New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients

Data presented at the ESMO 2016 Congress, the annual meeting of the European Society … and medical oncologist at Memorial Sloan Kettering Cancer Center.